Current treatment status-Undergoing active treatment-Progressive despite treatment Posts on Medivizor
Navigation Menu

Current treatment status-Undergoing active treatment-Progressive despite treatment Posts on Medivizor

What are the effects of treatment with brentuximab vedotin plus bendamustine on unresponsive HL?

Posted by on Jun 19, 2018 in Hodgkin's lymphoma | 0 comments

In a nutshell This study investigated the effects of pre-stem cell transplantation (pre-SCT) treatment with brentuximab vedotin (Adcetris) and bendamustine (Treanda) on patients with relapsing/refractory Hodgkin's Lymphoma (HL) following transplant. The main finding was that the drug combination was effective as a pre-SCT therapy. Some...

Read More

Does ibrutinib pre-treatment affect the outcomes of alloHCT in mantle cell lymphoma?

Posted by on May 31, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated the safety and effectiveness of alloHCT (allogeneic hematopoietic stem cell transplantation) in patients with mantle cell lymphoma (MCL) pre-treated with ibrutinib (Imbruvica). This study concluded that ibrutinib does not affect the safety of alloHCT. Some background Ibrutinib has become the standard of care for...

Read More

What type of stem cell transplant is most effective after early treatment failure in follicular lymphoma?

Posted by on May 30, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated the effectiveness of stem cell transplantation in follicular lymphoma patients who experienced early treatment failure after frontline chemoimmunotherapy. This study concluded that transplants using the patient's own stem cells or those from a matched sibling donor lead to better survival outcomes in these...

Read More

Radiotherapy for relapsed or refractory diffuse large b-cell lymphoma

Posted by on May 29, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated the effectiveness of consolidative or salvage radiotherapy for patients with relapsed or refractory (does not respond to treatment) diffuse large B-cell lymphoma. This study concluded that radiotherapy is an effective option for high-risk patients. Some background The most widely used treatment for diffuse large...

Read More

Is targeted therapy better at treating advanced NSCLC than current chemotherapy treatment?

Posted by on Apr 21, 2018 in Lung cancer | 0 comments

In a nutshell This study examined the effectiveness of the targeted therapy drug nivolumab (Opdivo) at treating advanced non-small-cell lung cancer, particularly for patients with cancer that has spread to the liver. The authors concluded that nivolumab led to an improved overall survival compared to chemotherapy for these patients. Some background...

Read More

What are the long-term outcomes for HL patients who experience treatment failure after an autologous stem cell transplant?

Posted by on Apr 18, 2018 in Hodgkin's lymphoma | 0 comments

In a nutshell This study analyzed the survival outcomes of Hodgkin’s lymphoma (HL) patients who experience treatment failure after high-dose chemotherapy (HDC) and autologous hematopoietic stem cell transplantation (autoSCT). This study concluded that a second stem cell transplant with or without brentuximab vedotin (Adcetris) may lead to better...

Read More

How safe and effective is ponatinib for chronic phase chronic myeloid leukemia patients?

Posted by on Apr 18, 2018 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the effectiveness and safety of ponatinib (Iclusig) for patients with chronic phase chronic myelogenous leukemia. This study concluded that ponatinib is safe and effective in this group of patients. Some background The Philadelphia chromosome (BCR-ABL1) is found in almost all patients with chronic...

Read More

Risk factors that influence outcomes for acute leukemia patients with relapse after hematopoietic stem cell transplant.

Posted by on Mar 17, 2018 in Leukemia | 0 comments

In a nutshell This study aimed to investigate risk factors that influence the outcome of acute leukemia patients who experience relapse after hematopoietic stem cell transplant. This study concluded that certain factors, such as older age and not acheiving remission after relapse treatment, are associated with worse survival outcomes. Some...

Read More

How safe and effective is the combination of ibrutinib, lenalidomide, and rituximab for relapsed or refractory mantle cell lymphoma?

Posted by on Mar 17, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated the safety and effectiveness of ibrutinib (Imbruvica), lenalidomide (Revlimid), and rituximab (Rituxan) given together to patients with relapsed or refractory (not responding to treatment) mantle cell lymphoma (MCL). The authors conclude that this combination is effective in these patients, but not better than the...

Read More